Preservation of function in experimental renal disease by dietary restriction of phosphate
- PMID: 619240
- DOI: 10.1056/NEJM197801192980302
Preservation of function in experimental renal disease by dietary restriction of phosphate
Abstract
We sought to determine the importance of calcium phosphate deposition in the functional deterioration of damaged or diseased kidneys. Using the remnant-kidney model in rats, we found that dietary phosphate restriction prevented proteinuria, renal calcification, histologic changes, functional deterioration and death in uremia. Histologic examination of the remnant kidney in the nonrestricted animals showed calcium and phosphorus deposits in the cortical tubular cells, basement membranes and interstitium. A similar degree and pattern of calcification have been found in preliminary studies of human end-stage kidneys. Our results suggest that the calcification produced by the altered phosphorus metabolism present in the uremic state incites an inflammatory and fibrotic reaction leading to destruction of the remnant kidney. Phosphate restriction prevents this response in the remnant kidney. The potential applicability of these findings to other forms of experimental renal disease and to clinical uremia remains to be explored.
Similar articles
-
Food restriction retards body growth and prevents end-stage renal pathology in remnant kidneys of rats regardless of protein intake.Lab Invest. 1989 Feb;60(2):184-95. Lab Invest. 1989. PMID: 2915513
-
Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.Nephrol Dial Transplant. 2003 Oct;18(10):2014-23. doi: 10.1093/ndt/gfg309. Nephrol Dial Transplant. 2003. PMID: 13679475
-
Influence of dietary protein/calorie intake on renal morphology and function in cats with 5/6 nephrectomy.Lab Invest. 1994 Mar;70(3):347-57. Lab Invest. 1994. PMID: 8145529
-
Role of phosphate retention in the progression of renal failure.J Lab Clin Med. 1993 Jul;122(1):16-26. J Lab Clin Med. 1993. PMID: 8320487 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
The Usefulness of Calcium/Magnesium Ratio in the Risk Stratification of Early Onset of Renal Replacement Therapy.Diagnostics (Basel). 2022 Oct 12;12(10):2470. doi: 10.3390/diagnostics12102470. Diagnostics (Basel). 2022. PMID: 36292159 Free PMC article.
-
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.Clin J Am Soc Nephrol. 2010 Jul;5(7):1268-76. doi: 10.2215/CJN.08241109. Epub 2010 May 6. Clin J Am Soc Nephrol. 2010. PMID: 20448073 Free PMC article.
-
Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification.Kidney Int. 2013 Dec;84(6):1145-53. doi: 10.1038/ki.2013.213. Epub 2013 Oct 9. Kidney Int. 2013. PMID: 24107846 Free PMC article.
-
Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease.Kidney Int. 2015 Oct;88(4):833-42. doi: 10.1038/ki.2015.165. Epub 2015 Jun 10. Kidney Int. 2015. PMID: 26061542
-
Dissociation of renal cyclic AMP and phosphate responses to parathyroid hormone in uremia.Calcif Tissue Int. 1979 Nov 26;29(2):147-54. doi: 10.1007/BF02408070. Calcif Tissue Int. 1979. PMID: 228820 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources